Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425586 | 0.86 | MAPKAPK2 (0.44) | ALDH1A1SMN1; SMN2MAPTLMNAEGFR | |
| SCHEMBL24386071 | 0.75 | MPO (0.31) | ALDH1A1MAPT | |
| SCHEMBL427194 | 0.73 | GRM2 (0.39) | ALDH1A1SMN1; SMN2MAPTMAPK1GAA | |
| SCHEMBL15073763 | 0.67 | HTR2C (0.39) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL874744 | 0.66 | KMT2A (0.47) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL7261706 | 0.66 | PRSS1 (0.35) | — | |
| SCHEMBL15073749 | 0.64 | HTR2C (0.38) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL2854246 | 0.63 | CCNT1 (0.65) | ALDH1A1HTR2CTNKS2EGFR | |
| SCHEMBL23370552 | 0.62 | KMT2A (0.50) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 | |
| SCHEMBL14380287 | 0.62 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2MAPTLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| EP-2619181-A1 | NOVEL MICROBIOCIDES | Syngenta Participations AG (CH) | 2013-07-31 | — | — | EP | disclosed |
| WO-2013092460-A1 | CYCLIC BISOXIME MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2012117021-A2 | NOVEL MICROBIOCIDAL OXIME ETHERS | SYNGENTA PARTICIPATIONS AG (CH) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | ALDH1A1 1154/4885SMN1; SMN2 4778/4885MAPT 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.